<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="Cache-Control" content="no-cache, no-store, must-revalidate">
    <meta http-equiv="Pragma" content="no-cache">
    <meta http-equiv="Expires" content="0">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Bridging Therapy - CRLM LT Clinical Resource</title>
    <link rel="stylesheet" href="../css/style.css?v=1765115033437">
</head>
<body>
    <!-- Navigation -->
    <nav class="navbar">
        <div class="container">
            <div class="logo">CRLM LT Resource</div>
            <button class="hamburger" id="hamburger" aria-label="Toggle menu">
                <span></span>
                <span></span>
                <span></span>
            </button>
            <ul class="nav-menu" id="navMenu">
                <li><a href="../index.html">Home</a></li>
                <li><a href="overview.html">Overview</a></li>
                <li><a href="selection-criteria.html">Selection Criteria</a></li>
                <li><a href="outcomes.html">Clinical Outcomes</a></li>
                <li><a href="tools.html">Tools</a></li>
                <li><a href="faq.html">FAQ</a></li>
                <li><a href="glossary.html">Glossary</a></li>
                <li><a href="case-studies.html">Cases</a></li>
                <li><a href="bridging-therapy.html" class="active">Bridging Therapy</a></li>
                <li><a href="lt-vs-resection.html">LT vs Resection</a></li>
                <li><a href="survival-curves.html">Survival Curves</a></li>
                <li><a href="pdf-resources.html">PDF Resources</a></li>
                <li><a href="patient-flowchart.html">Patient Flowchart</a></li>
                <li><a href="resources.html">Resources</a></li>
                <li><a href="about-research-group.html">About Research Group</a></li>
            </ul>
        </div>
    </nav>

    <!-- Main Content -->
    <main class="content">
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">Home</a> / Bridging Therapy
            </div>

            <h1>Bridging Therapy and Disease Management</h1>

            <section class="section">
                <p>Bridging therapy refers to systemic chemotherapy and other treatments administered to patients while awaiting liver transplantation. This page provides comprehensive guidance on chemotherapy regimens, locoregional therapies, and management strategies for patients with unresectable colorectal liver metastases awaiting LT.</p>
            </section>

            <!-- Systemic Chemotherapy -->
            <section class="section">
                <h2>Systemic Chemotherapy Regimens</h2>

                <p>Modern chemotherapy regimens for CRLM are highly effective and form the backbone of bridging therapy. The choice of regimen depends on patient factors, disease characteristics, and treatment goals.</p>

                <h3>Doublet Regimens</h3>

                <div class="treatment-box">
                    <h4>FOLFOX (Fluorouracil, Leucovorin, Oxaliplatin)</h4>
                    <p><strong>Composition:</strong> 5-FU + leucovorin + oxaliplatin</p>
                    <p><strong>Cycle:</strong> Every 2 weeks</p>
                    <p><strong>Response Rate:</strong> 40-50%</p>
                    <p><strong>Advantages:</strong>
                        <ul>
                            <li>Well-established efficacy and safety</li>
                            <li>Predictable toxicity profile</li>
                            <li>Compatible with targeted therapy</li>
                            <li>Suitable for patients with good performance status</li>
                        </ul>
                    </p>
                    <p><strong>Toxicities:</strong>
                        <ul>
                            <li>Peripheral neuropathy (cumulative, dose-dependent)</li>
                            <li>Myelosuppression</li>
                            <li>Diarrhea</li>
                            <li>Hand-foot syndrome</li>
                        </ul>
                    </p>
                    <p><strong>Monitoring:</strong> CBC, liver function tests, neuropathy assessment every 2 cycles</p>
                </div>

                <div class="treatment-box">
                    <h4>FOLFIRI (Fluorouracil, Leucovorin, Irinotecan)</h4>
                    <p><strong>Composition:</strong> 5-FU + leucovorin + irinotecan</p>
                    <p><strong>Cycle:</strong> Every 2 weeks</p>
                    <p><strong>Response Rate:</strong> 35-45%</p>
                    <p><strong>Advantages:</strong>
                        <ul>
                            <li>No cumulative neuropathy (unlike FOLFOX)</li>
                            <li>Effective in KRAS-mutant tumors</li>
                            <li>Good option for patients with oxaliplatin contraindications</li>
                        </ul>
                    </p>
                    <p><strong>Toxicities:</strong>
                        <ul>
                            <li>Diarrhea (can be severe)</li>
                            <li>Myelosuppression</li>
                            <li>Cholinergic syndrome (early diarrhea)</li>
                            <li>Nausea/vomiting</li>
                        </ul>
                    </p>
                    <p><strong>Monitoring:</strong> CBC, liver function tests, diarrhea assessment every 2 cycles</p>
                </div>

                <h3>Triplet Regimens</h3>

                <div class="treatment-box">
                    <h4>FOLFOXIRI (Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan)</h4>
                    <p><strong>Composition:</strong> 5-FU + leucovorin + oxaliplatin + irinotecan</p>
                    <p><strong>Cycle:</strong> Every 2 weeks</p>
                    <p><strong>Response Rate:</strong> 54-65% (highest among standard regimens)</p>
                    <p><strong>Indications:</strong>
                        <ul>
                            <li>Extensive unresectable CRLM</li>
                            <li>Patients with good performance status (ECOG 0-1)</li>
                            <li>Fit patients awaiting LT</li>
                            <li>Rapid disease progression</li>
                        </ul>
                    </p>
                    <p><strong>Advantages:</strong>
                        <ul>
                            <li>Highest response rates</li>
                            <li>Improved progression-free survival</li>
                            <li>Better disease control during waitlist period</li>
                            <li>May improve prognostic scores (Oslo, FCRS, PET-MTV)</li>
                        </ul>
                    </p>
                    <p><strong>Toxicities:</strong>
                        <ul>
                            <li>Grade 3-4 toxicity in 70-80% of patients</li>
                            <li>Neutropenia</li>
                            <li>Diarrhea</li>
                            <li>Peripheral neuropathy</li>
                            <li>Requires close monitoring and supportive care</li>
                        </ul>
                    </p>
                    <p><strong>Monitoring:</strong> CBC, liver function tests, neuropathy assessment every 2 cycles; consider dose modifications for toxicity</p>
                </div>

                <h3>Targeted Therapies</h3>

                <p>Modern chemotherapy regimens are often combined with targeted agents to improve efficacy:</p>

                <div class="treatment-box">
                    <h4>Anti-EGFR Therapy (Cetuximab, Panitumumab)</h4>
                    <p><strong>Indication:</strong> KRAS wild-type tumors</p>
                    <p><strong>Mechanism:</strong> Inhibits epidermal growth factor receptor signaling</p>
                    <p><strong>Efficacy:</strong> Improves response rate and OS in KRAS wild-type patients</p>
                    <p><strong>Toxicities:</strong>
                        <ul>
                            <li>Acneiform rash (80% of patients)</li>
                            <li>Hypomagnesemia</li>
                            <li>Infusion reactions (cetuximab)</li>
                        </ul>
                    </p>
                    <p><strong>Monitoring:</strong> Magnesium levels, skin assessment, infusion reactions</p>
                </div>

                <div class="treatment-box">
                    <h4>Anti-VEGF Therapy (Bevacizumab, Aflibercept, Ramucirumab)</h4>
                    <p><strong>Indication:</strong> All patients (regardless of KRAS status)</p>
                    <p><strong>Mechanism:</strong> Inhibits vascular endothelial growth factor signaling; blocks angiogenesis</p>
                    <p><strong>Efficacy:</strong> Improves response rate and OS when combined with chemotherapy</p>
                    <p><strong>Toxicities:</strong>
                        <ul>
                            <li>Hypertension</li>
                            <li>Proteinuria</li>
                            <li>Bleeding risk</li>
                            <li>Thrombosis</li>
                            <li>GI perforation (rare)</li>
                        </ul>
                    </p>
                    <p><strong>Monitoring:</strong> Blood pressure, urinalysis, bleeding signs, thrombosis risk</p>
                </div>
            </section>

            <!-- Bridging Therapy Duration and Timing -->
            <section class="section">
                <h2>Bridging Therapy Duration and Timing</h2>

                <h3>Minimum Duration</h3>
                <p><strong>Recommended:</strong> Minimum 3 months of systemic chemotherapy before LT consideration</p>
                <ul>
                    <li>Allows assessment of chemotherapy response</li>
                    <li>Identifies patients with aggressive disease</li>
                    <li>Enables disease control before transplant</li>
                </ul>

                <h3>Optimal Duration</h3>
                <p><strong>Recommended:</strong> 6-12 months of bridging therapy</p>
                <ul>
                    <li>Allows maximum disease burden reduction</li>
                    <li>Provides time for transplant evaluation</li>
                    <li>Optimizes prognostic scores</li>
                    <li>Accounts for waitlist time</li>
                </ul>

                <h3>Extended Bridging Therapy</h3>
                <p><strong>Indications:</strong> Consider extending beyond 12 months if:</p>
                <ul>
                    <li>Continued response to chemotherapy</li>
                    <li>Improving prognostic scores</li>
                    <li>Decreasing PET-MTV</li>
                    <li>Excellent tolerance to treatment</li>
                    <li>Waitlist time still pending</li>
                </ul>

                <h3>Timing of LT Relative to Chemotherapy</h3>
                <p><strong>Optimal Approach:</strong> LT should occur shortly after optimal disease control achieved</p>
                <ul>
                    <li>Avoid excessive delays that allow disease progression</li>
                    <li>Complete chemotherapy cycles before transplant if possible</li>
                    <li>Coordinate with transplant center for optimal timing</li>
                    <li>Consider patient factors (toxicity, performance status)</li>
                </ul>
            </section>

            <!-- Locoregional Therapies -->
            <section class="section">
                <h2>Locoregional Therapies</h2>

                <p>Locoregional therapies can be used as adjuncts to systemic chemotherapy to enhance disease control during the bridging period.</p>

                <h3>TACE (Transarterial Chemoembolization)</h3>
                <div class="treatment-box">
                    <p><strong>Mechanism:</strong> Delivers chemotherapy directly to tumors via hepatic artery while blocking blood supply</p>
                    <p><strong>Indications:</strong>
                        <ul>
                            <li>Adjunct to systemic chemotherapy</li>
                            <li>Patients with stable disease on chemo</li>
                            <li>Bridge to LT in select cases</li>
                        </ul>
                    </p>
                    <p><strong>Efficacy:</strong> Improves local control; may improve progression-free survival</p>
                    <p><strong>Toxicities:</strong>
                        <ul>
                            <li>Post-embolization syndrome (fever, pain, nausea)</li>
                            <li>Hepatic dysfunction</li>
                            <li>Ischemic complications</li>
                        </ul>
                    </p>
                </div>

                <h3>SIRT (Selective Internal Radiation Therapy)</h3>
                <div class="treatment-box">
                    <p><strong>Mechanism:</strong> Delivers radioactive microspheres to liver tumors via hepatic artery</p>
                    <p><strong>Indications:</strong>
                        <ul>
                            <li>Adjunct to systemic chemotherapy</li>
                            <li>Patients with extensive intrahepatic disease</li>
                            <li>Bridge to LT in select cases</li>
                        </ul>
                    </p>
                    <p><strong>Efficacy:</strong> Improves local control; may improve time to progression</p>
                    <p><strong>Advantages:</strong>
                        <ul>
                            <li>Minimally invasive</li>
                            <li>Well-tolerated</li>
                            <li>Can be repeated if needed</li>
                        </ul>
                    </p>
                </div>

                <h3>RFA (Radiofrequency Ablation)</h3>
                <div class="treatment-box">
                    <p><strong>Mechanism:</strong> Uses heat to destroy tumors percutaneously</p>
                    <p><strong>Indications:</strong>
                        <ul>
                            <li>Small lesions (< 3-4 cm)</li>
                            <li>Limited number of tumors</li>
                            <li>Adjunct to systemic therapy</li>
                        </ul>
                    </p>
                    <p><strong>Efficacy:</strong> Good local control for small lesions</p>
                    <p><strong>Limitations:</strong>
                        <ul>
                            <li>Not suitable for extensive disease</li>
                            <li>Risk of incomplete ablation</li>
                            <li>Limited role in bridging therapy for CRLM</li>
                        </ul>
                    </p>
                </div>

                <h3>Hepatic Artery Infusion (HAI)</h3>
                <div class="treatment-box">
                    <p><strong>Mechanism:</strong> Delivers chemotherapy directly into hepatic artery via implanted pump</p>
                    <p><strong>Indications:</strong>
                        <ul>
                            <li>Extensive intrahepatic disease</li>
                            <li>Systemic chemotherapy resistance</li>
                            <li>Bridge to LT in select cases</li>
                        </ul>
                    </p>
                    <p><strong>Efficacy:</strong> High response rates; improves time to progression</p>
                    <p><strong>Considerations:</strong>
                        <ul>
                            <li>Requires surgical placement of pump</li>
                            <li>Pump-related complications</li>
                            <li>Requires specialized expertise</li>
                        </ul>
                    </p>
                </div>
            </section>

            <!-- Response Assessment -->
            <section class="section">
                <h2>Response Assessment During Bridging Therapy</h2>

                <h3>Imaging Assessment</h3>
                <p><strong>Frequency:</strong> Every 2-3 months during bridging therapy</p>
                <p><strong>Modalities:</strong>
                    <ul>
                        <li>Contrast-enhanced CT or MRI of liver</li>
                        <li>18F-FDG PET/CT (baseline and periodic)</li>
                        <li>Chest imaging to exclude pulmonary metastases</li>
                    </ul>
                </p>

                <h3>Response Criteria</h3>
                <p><strong>RECIST 1.1 Criteria:</strong> Standard assessment for solid tumors</p>
                <ul>
                    <li><strong>Complete Response (CR):</strong> Disappearance of all lesions</li>
                    <li><strong>Partial Response (PR):</strong> ≥ 30% reduction in sum of longest diameters</li>
                    <li><strong>Stable Disease (SD):</strong> < 30% reduction and < 20% increase</li>
                    <li><strong>Progressive Disease (PD):</strong> ≥ 20% increase in sum of longest diameters</li>
                </ul>

                <h3>Prognostic Score Evolution</h3>
                <p><strong>Reassess Prognostic Scores During Bridging:</strong></p>
                <ul>
                    <li><strong>Oslo Score:</strong> Recalculate every 3 months; improved scores indicate favorable response</li>
                    <li><strong>FCRS:</strong> May improve with disease burden reduction</li>
                    <li><strong>PET-MTV:</strong> Should decrease with effective chemotherapy; < 70 cm³ is favorable</li>
                </ul>

                <p><strong>Clinical Significance:</strong> Patients with improving prognostic scores during bridging therapy are upgraded from marginal to good candidates for LT.</p>
            </section>

            <!-- Management of Recurrence Post-LT -->
            <section class="section">
                <h2>Management of Recurrent Disease After LT</h2>

                <p>Despite excellent OS after LT, recurrence occurs in 78.3% of patients. Aggressive management of recurrent disease is warranted given the prolonged survival after relapse (median 37.1 months).</p>

                <h3>Surveillance Strategy</h3>
                <p><strong>Recommended Surveillance:</strong></p>
                <ul>
                    <li><strong>Months 0-12:</strong> CT/MRI every 2-3 months; CEA every month</li>
                    <li><strong>Months 12-24:</strong> CT/MRI every 3 months; CEA every 2 months</li>
                    <li><strong>After 24 months:</strong> CT/MRI every 3-4 months; CEA every 3 months</li>
                    <li><strong>PET-CT:</strong> Consider annually or if CEA elevation</li>
                </ul>

                <h3>Sites of Recurrence</h3>
                <p><strong>Distribution of Recurrence:</strong></p>
                <ul>
                    <li><strong>Pulmonary metastases:</strong> 40-50% of recurrences</li>
                    <li><strong>Peritoneal disease:</strong> 20-30% of recurrences</li>
                    <li><strong>Distant metastases:</strong> 10-20% of recurrences</li>
                    <li><strong>Graft recurrence:</strong> 10-15% of recurrences</li>
                </ul>

                <h3>Treatment of Recurrent Disease</h3>

                <div class="treatment-box">
                    <h4>Pulmonary Metastases</h4>
                    <p><strong>Management:</strong> Thoracoscopic or open resection if feasible</p>
                    <ul>
                        <li>Resection improves OS in selected patients</li>
                        <li>Consider resection if < 4 lesions and good performance status</li>
                        <li>Systemic chemotherapy for unresectable disease</li>
                    </ul>
                </div>

                <div class="treatment-box">
                    <h4>Peritoneal Disease</h4>
                    <p><strong>Management:</strong> Consider cytoreductive surgery + HIPEC (hyperthermic intraperitoneal chemotherapy)</p>
                    <ul>
                        <li>Selected patients with limited peritoneal involvement</li>
                        <li>Systemic chemotherapy for extensive disease</li>
                        <li>Palliative care for unresectable disease</li>
                    </ul>
                </div>

                <div class="treatment-box">
                    <h4>Systemic Chemotherapy</h4>
                    <p><strong>Management:</strong> Restart or continue chemotherapy</p>
                    <ul>
                        <li>Resume previous regimen if good response</li>
                        <li>Switch to alternative regimen if prior resistance</li>
                        <li>Consider clinical trials for novel agents</li>
                        <li>Coordinate with transplant team regarding immunosuppression</li>
                    </ul>
                </div>

                <div class="treatment-box">
                    <h4>Locoregional Therapy</h4>
                    <p><strong>Management:</strong> TACE, SIRT, or RFA for limited disease</p>
                    <ul>
                        <li>Useful for graft recurrence</li>
                        <li>Can be combined with systemic therapy</li>
                        <li>May improve progression-free survival</li>
                    </ul>
                </div>
            </section>

            <!-- Immunosuppression Considerations -->
            <section class="section">
                <h2>Immunosuppression and Anti-Tumor Immunity</h2>

                <p>Balancing immunosuppression to prevent rejection while maintaining anti-tumor immunity is a unique challenge in LT for CRLM.</p>

                <h3>Standard Immunosuppressive Regimens</h3>
                <ul>
                    <li><strong>Calcineurin inhibitor:</strong> Tacrolimus (target level 8-12 ng/mL)</li>
                    <li><strong>Antiproliferative agent:</strong> Mycophenolate mofetil or azathioprine</li>
                    <li><strong>Corticosteroids:</strong> Tapered to low maintenance dose</li>
                </ul>

                <h3>Everolimus: mTOR Inhibitor with Anti-Tumor Properties</h3>
                <p><strong>Emerging Role:</strong> Everolimus is increasingly used in CRLM transplant patients</p>
                <ul>
                    <li><strong>Mechanism:</strong> mTOR inhibition; anti-proliferative effects</li>
                    <li><strong>Potential Anti-Tumor Activity:</strong> May reduce recurrence risk</li>
                    <li><strong>Advantages:</strong> Allows tacrolimus dose reduction; potential anti-cancer benefit</li>
                    <li><strong>Toxicities:</strong> Stomatitis, dyslipidemia, pneumonitis</li>
                </ul>

                <h3>Post-LT Chemotherapy</h3>
                <p><strong>Considerations:</strong></p>
                <ul>
                    <li>Chemotherapy can be safely administered post-LT</li>
                    <li>Coordinate with transplant team regarding drug interactions</li>
                    <li>Monitor for increased toxicity due to immunosuppression</li>
                    <li>Assess graft function before initiating chemotherapy</li>
                </ul>
            </section>

            <section class="section call-to-action">
                <h2>Next Steps</h2>
                <p>For more information on patient selection and prognostic assessment, visit the <a href="selection-criteria.html">Selection Criteria</a> page or use the <a href="tools.html">Interactive Tools</a>. For case examples of bridging therapy, see the <a href="case-studies.html">Case Studies</a> page.</p>
            </section>
        </div>
    </main>

    <!-- Footer -->
    <footer class="footer">
        <div class="container">
            <p>&copy; 2025 CRLM LT Clinical Resource. Evidence-based information for transplant teams.</p>
            <p class="author"><strong>Created by:</strong> Tor Magnus Smedman, MD PhD | Transplant Oncology Research Group, Oslo University Hospital</p>
            <p class="disclaimer">This resource is for educational purposes. Clinical decisions should be made in consultation with a multidisciplinary team.</p>
        </div>
    </footer>

    <script src="../js/main.js?v=1765115033437"></script>
    <script>
        // Hamburger menu toggle
        const hamburger = document.getElementById("hamburger");
        const navMenu = document.getElementById("navMenu");
        
        if (hamburger && navMenu) {
            hamburger.addEventListener("click", function() {
                navMenu.classList.toggle("active");
                hamburger.classList.toggle("active");
            });
            
            // Close menu when a link is clicked
            const navLinks = navMenu.querySelectorAll("a");
            navLinks.forEach(link => {
                link.addEventListener("click", function() {
                    navMenu.classList.remove("active");
                    hamburger.classList.remove("active");
                });
            });
        }
    </script>
    <script>
    </script>
</body>
</html>
